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Percutaneous
Revascularization for
Peripheral Arterial Disease
Paclitaxel Saves the Day*
Ehtisham Mahmud, MD
La Jolla, California
Patients presenting with femoropopliteal (FP) disease often
require revascularization for lifestyle-limiting claudication
medical therapy that failed, or for critical limb ischemia.
Percutaneous revascularization for FP disease has been
fraught with challenges since the initial description of
percutaneous transluminal balloon angioplasty (PTA) of the
FP artery. Due to high rates of arterial dissection and
restenosis after PTA, randomized comparisons of self-
expanding stents and PTA for FP disease have been
performed and have demonstrated the superiority of stent-
ing (1,2). Nevertheless, restenosis rates with self-expanding
nitinol stents are 19% to 37% at 1-year follow-up, and
options for the treatment of FP restenosis are limited (1,2).
See pages 274 and 282
Additionally, because this vessel undergoes significant tor-
sion, extension, and flexion during daily activity, FP stent
fractures have been reported that are associated with reste-
nosis (3) and potential distal embolization of stent frag-
ments. Self-expanding stent grafts covered with expanded
polytetrafluoroethylene (ePTFE) (Viabahn, Gore Medical,
Newark, Delaware) lead to comparable outcomes as surgical
FP bypass using prosthetic conduits, (4) but can result in
occlusion of collaterals and are not an appropriate initial
treatment option for most patients with FP disease. Clinical
outcomes from registries evaluating the use of extraction,
rotational, and laser atherectomy for the treatment of FP
disease have been encouraging but have not been compared
in an adequately powered randomized clinical trial against
PTA.
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disease with the sirolimus-eluting self-expanding SMART
stent (Cordis, Miami, Florida) randomized against its bare-
metal stent counterpart (SIRROCO I and II trials). The
initial results from these trials were promising, with superior
inhibition of neointimal proliferation and lower binary
restenosis at 6 months with the sirolimus-eluting stent (5,6).
However, at 18-month follow-up, the sirolimus-eluting
stent group demonstrated a “catch-up” phenomenon result-
ing in comparable clinical and angiographic event rates in
the 2 groups (5,6). Though sirolimus is highly effective in
reducing coronary restenosis, its antiproliferative effect was
inadequate in the FP segment. These trials highlighted the
importance of longer term follow-up when evaluating re-
vascularization techniques, drugs and devices in the periph-
eral as opposed to the coronary vasculature.
Paclitaxel is a highly lipophilic antimitotic drug that alters
microtubule function. It inhibits vascular smooth muscle
cell migration and proliferation (7), with pre-clinical data
supporting its efficacy in reducing restenosis when coated on
a balloon and delivered locally (8). Initial pilot studies
demonstrated that use of a paclitaxel-eluting balloon (PEB)
led to lower late luminal loss (0.4  1.2 mm vs. 1.7  1.8
mm; p  0.001 and 0.5  1.1 mm vs. 1.0  1.1 mm; p 
0.031) and restenosis (4% vs. 37%; p  0.001 and 19% vs.
47%; p  0.035) (9,10) at 6-month follow-up as compared
with an uncoated balloon for the treatment of symptomatic
FP disease. Additionally, in a pivotal study enrolling pa-
tients with FP disease, at 1-year follow-up, the Zilver PTX
randomized trial demonstrated superior primary patency
(83.1% vs. 32.8%, p 0.001) and event-free survival (90.4%
vs. 82.6%; p  0.004) for the polymer-free paclitaxel-
eluting nitinol self-expanding stent compared with PTA. In
a small subgroup in which PTA failed, the angiographic and
clinical superiority of the paclitaxel drug-eluting stent was
also shown compared with its bare-metal stent control (11).
In this issue of JACC: Cardiovascular Interventions, 2
studies addressing long-term outcomes after the treatment
of native FP disease with a PEB, and FP in-stent restenosis
with a nonpolymeric paclitaxel-eluting stent, respectively,
are reported (12,13). In a multicenter registry of 105
patients (114 lesions), Micari et al. (12) treated FP lesions
(76  38 mm length; 5.2  0.6 mm diameter reference
essels; 92.5  8.2% stenosis) with the In.Pact Admiral
PEB (Medtronic, Minneapolis, Minnesota) and bail-out
stenting (12.3% lesions). Procedural success was achieved in
all, and primary patency at 1 year was 83.7%. At 2-year
follow-up, primary patency was maintained in 72.4%,
whereas secondary patency was 84.7%. Importantly, for
subjects without restenosis or target lesion revascularization
at 1 year, primary patency was 85.1% with a target lesion
revascularization rate of 7.1% at 2-year follow-up, demon-
strating the absence of a catch-up phenomenon with the
PEB. At 2-year follow-up, major adverse events were
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291reported in 17.5% with significant improvements in ankle
brachial index, claudication distance, Rutherford class, and
quality of life functional measurements.
In the second study, Zeller et al. (13) report long-term
outcomes for 108 subjects (119 lesions) enrolled with
in-stent restenosis of FP disease (133.0  91.7 mm length;
.6  0.7 mm reference vessel diameter; 87.0  12.4%
stenosis; total occlusion in 31.1%) and treated with the
Zilver PTX drug-eluting stent (Cook Medical, Blooming-
ton, Indiana). These data are reported from a larger multi-
center registry (n  787) evaluating this stent for FP
isease. In the cohort of subjects with FP in-stent resteno-
is, procedural success was achieved in 98.2%, and primary
atency at 1 year was reported to be 78.8%. At 2-year
ollow-up, freedom from major adverse events was 60.8%
all events due to clinically driven target lesion revascular-
zation). No predictors of recurrent in-stent restenosis were
dentified. At 2-year follow-up, significant improvements in
nkle brachial index, walking and climbing distance, and
utherford class were observed.
Both of these studies demonstrate that a new paradigm
or the treatment of FP disease involving local delivery of
aclitaxel is emerging. These studies were multicenter, with
road inclusion criteria, inclusive of long lesions and eval-
ated both anatomic and clinical endpoints. However, both
tudies lacked control groups and had small sample sizes, so
either was adequately powered to identify predictors of
ailure. Micari et al. (12) report 2-year follow-up results,
nd it is reassuring that treatment of de novo FP disease
ith the PEB leads to no increase in late restenosis, and
he early clinical benefit is maintained at longer term
ollow-up. By contrast, the treatment of FP in-stent
estenosis remains challenging. Zeller et al. (13) evalu-
ted the Zilver PTX stent in a recalcitrant group of
atients who had long lesions with restenosis, occlusions
n a third, and 2 previous interventions in half the
ohort. Though procedural success and primary patency
t 1 year were high, 2-year follow-up yielded less favor-
ble results, with an almost 40% rate of target lesion
evascularization.
Both the PEB and the Zilver PTX stent had polymer-
ree paclitaxel coated at a concentration of 3 g/mm2 of
surface area. It is unclear whether the drug release kinetics
are such that a short exposure of paclitaxel transferred from
the PEB to the vessel wall leads to a different vascular
response compared with the more sustained release of the
drug from the stent. This is important because paclitaxel
has a narrow therapeutic range, and at higher concentra-
tion, it can disrupt the internal elastic lamina and reduce
intimal and medial smooth muscle cells and collagen
content (14). Furthermore, in a murine model, transcrip-
tional analysis by real-time reverse transcription-PCR
showed an increase in proapoptotic mRNA transcripts
(caspase 3, FAS, BAX) in paclitaxel-treated arteries (14).Therefore, though paclitaxel reduces restenosis in the
peripheral vasculature, the timing of optimal drug deliv-
ery is critical in minimizing excessive vascular exposure to
the drug and in reducing the risk of adverse vascular
injury. Additionally, the exact mechanism of paclitaxel
transfer and retention in the vessel wall is still unclear.
The roles of drug concentration and carrier and diffusion
kinetics also require additional understanding.
The long-term results of the currently reported studies
appear to favor the treatment of de novo FP disease with the
PEB, with the expectation of assisted patency of 84.7% in
intermediate length lesions at 2-year follow-up. This is accom-
panied by favorable clinical endpoints, including low future
rates of repeat revascularization and improved quality of life
indexes. As opposed to other current treatment modalities for
FP disease, including PTA, atherectomy, bare-metal stenting,
and drug-eluting stenting, these data are extremely favorable. It
is also clear that in-stent restenosis of the FP vascular territory
remains difficult to treat. Though the Zilver PTX stent is an
efficacious advance in the treatment of FP disease, using it for
in-stent restenosis still results in high repeat revascularization
at 2-year follow-up. However, the extremely low rate of stent
fracture (1.2%) and improvements in other clinical parameters,
including ankle brachial index and walking distance, are
favorable at 2-year follow-up. By contrast, Stabile et al. (15)
reported 1-year primary patency of 92.1% with the treatment
of FP in-stent restenosis using a PEB. Longer term follow-up
from that and other studies should shed light on the utility of
PEB for the treatment of FP in-stent restenosis. Paclitaxel is a
superior drug compared with sirolimus for the prevention of
restenosis of lower extremity peripheral arterial disease, and the
investigators of the current studies should be congratulated on
prospectively collecting multicenter data with an adequate
period of long-term follow-up. Future studies are required to
evaluate the role of adjunctive debulking before the use of
either the PEB or the paclitaxel-eluting stent in FP disease.
These need to be appropriately powered randomized trials, and
could also be an opportunity to better define the role of dual
antiplatelet therapy in reducing long-term adverse events after
peripheral arterial intervention.
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